OSI Pharmaceuticals: Roche Has Received Negative CHMP Opinion in European Union on Tarceva(R) in Pancreatic Cancer
01-Aug-2006 -
OSI Pharmaceuticals, Inc. announced that Roche, its international partner for Tarceva(R) (erlotinib), received a negative opinion from the European Committee for Medicinal Products for Human Use (CHMP), regarding approval of Tarceva in combination with gemcitabine chemotherapy as first-line, ...
chemotherapy
clinical trials
lung cancer
+1